<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="Therefore, particular attention should be given to cardiovascular protection during" exact="treatment" post="for COVID-19. Subject terms Infection Infectious diseases Cardiovascular diseases"/>
 <result pre="the underlying mechanisms is of the greatest importance, so that" exact="treatment" post="of these patients can be timely and effective and"/>
 <result pre="a functional receptor for coronaviruses4, including SARS-CoV and SARS-CoV-2. SARS-CoV-2" exact="infection" post="is triggered by binding of the spike protein of"/>
 <result pre="MERS-CoV have similar pathogenicity, and the myocardial damage caused by" exact="infection" post="with these viruses undoubtedly increases the difficulty and complexity"/>
 <result pre="myocardial injury1. In addition, among the confirmed cases of SARS-CoV-2" exact="infection" post="reported by the National Health Commission of China (NHC),"/>
 <result pre="progression. The mechanism of acute myocardial injury caused by SARS-CoV-2" exact="infection" post="might be related to ACE2. ACE2 is widely expressed"/>
 <result pre="12-year follow-up survey of 25 patients who recovered from SARS-CoV" exact="infection" post="found that 68% had hyperlipidaemia, 44% had cardiovascular system"/>
 <result pre="history of SARS-CoV infection7. However, the mechanisms by which SARS-CoV" exact="infection" post="leads to disorders of lipid and glucose metabolism are"/>
 <result pre="system, and attention should be given to cardiovascular protection during" exact="treatment" post="for COVID-19. Patients with pre-existing CVD A meta-analysis showed"/>
 <result pre="COVID-19. Patients with pre-existing CVD A meta-analysis showed that MERS-CoV" exact="infection" post="was more likely to occur in patients with underlying"/>
 <result pre="occur in patients with underlying CVD8. In patients with MERS-CoV" exact="infection" post="and severe symptoms, 50% had hypertension and diabetes and"/>
 <result pre="data released by the NHC, 35% of patients with SARS-CoV-2" exact="infection" post="had a history of hypertension and 17% had a"/>
 <result pre="patients with cardiac insufficiency who have underlying heart disease, SARS-CoV-2" exact="infection" post="might act as a precipitating factor to worsen the"/>
 <result pre="condition and lead to death. Drug-related heart damage during COVID-19" exact="treatment" post="is a concern. In particular, the use of antiviral"/>
 <result pre="cause cardiac insufficiency, arrhythmia or other cardiovascular disorders. Therefore, during" exact="treatment" post="of COVID-19, especially with the use of antivirals, the"/>
 <result pre="specific mechanisms are uncertain. Patients with underlying CVD and SARS-CoV-2" exact="infection" post="have an adverse prognosis. Therefore, particular attention should be"/>
 <result pre="Therefore, particular attention should be given to cardiovascular protection during" exact="treatment" post="for COVID-19. Related link Pneumonitis Diagnosis and Treatment Program"/>
</results>
